208 related articles for article (PubMed ID: 35870900)
1. Metabolic activity determines survival depending on the level of lymph node involvement in cervical cancer.
Martinez A; Chantalat E; Angeles MA; Ferron G; Ducassou A; Daix M; Attal J; Bétrian S; Lusque A; Gabiache E
BMC Cancer; 2022 Jul; 22(1):810. PubMed ID: 35870900
[TBL] [Abstract][Full Text] [Related]
2. Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer.
Martinez A; Voglimacci M; Lusque A; Ducassou A; Gladieff L; Dupuis N; Angeles MA; Martinez C; Tanguy Le Gac Y; Chantalat E; Hitzel A; Courbon F; Ferron G; Gabiache E
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1252-1260. PubMed ID: 31915897
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of the Sum of Metabolic Tumor Volume of Primary Tumor and Lymph Nodes Using 18F-FDG PET/CT in Patients With Cervical Cancer.
Hong JH; Min KJ; Lee JK; So KA; Jung US; Kim S; Eo JS
Medicine (Baltimore); 2016 Mar; 95(9):e2992. PubMed ID: 26945420
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?
Voglimacci M; Gabiache E; Lusque A; Ferron G; Ducassou A; Querleu D; Motton S; Chantalat E; Courbon F; Martinez A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1551-1559. PubMed ID: 30729273
[TBL] [Abstract][Full Text] [Related]
5.
Leray H; Gabiache E; Courbon F; Brenot-Rossi I; Colineaux H; Lepage B; Lambaudie E; Martinez A; Voglimacci M; Weyl A; Deslandres M; Ducassou A; Motton S; Vaysse C; Chantalat E
J Nucl Med; 2020 Oct; 61(10):1442-1447. PubMed ID: 32034109
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
[TBL] [Abstract][Full Text] [Related]
7. Metabolic parameters of [
Markus M; Sartor H; Bjurberg M; Trägårdh E
Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
[TBL] [Abstract][Full Text] [Related]
9. Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis.
Carpenter DJ; Jacobs CD; Wong TZ; Craciunescu O; Chino JP
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):356-366. PubMed ID: 31254659
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of Primary Tumors and Regional Lymph Nodes in Patients with Locally Advanced Cervical Cancer Who Are Treated with Concurrent Chemoradiotherapy.
Chong GO; Jeong SY; Park SH; Lee YH; Lee SW; Hong DG; Kim JC; Lee YS; Cho YL
PLoS One; 2015; 10(9):e0137743. PubMed ID: 26368542
[TBL] [Abstract][Full Text] [Related]
11. Tumor total lesion glycolysis and number of positive pelvic lymph nodes on pretreatment positron emission tomography/computed tomography (PET/CT) predict survival in patients with locally advanced cervical cancer.
De Cuypere M; Lovinfosse P; Gennigens C; Hermesse J; Rovira R; Duch J; Goffin F; Hustinx R; Kridelka F
Int J Gynecol Cancer; 2020 Nov; 30(11):1705-1712. PubMed ID: 33033165
[TBL] [Abstract][Full Text] [Related]
12. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
Dag Z; Yilmaz B; Dogan AK; Aksan DU; Ozkurt H; Kızılkaya HO; Arslan D
Brachytherapy; 2019; 18(2):154-162. PubMed ID: 30594422
[TBL] [Abstract][Full Text] [Related]
14. (
Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy.
Onal C; Guler OC; Reyhan M; Yapar AF
Gynecol Oncol; 2015 Apr; 137(1):40-6. PubMed ID: 25641567
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy.
Guler OC; Torun N; Yildirim BA; Onal C
Br J Radiol; 2018 Apr; 91(1084):20170552. PubMed ID: 29293366
[TBL] [Abstract][Full Text] [Related]
17. Added value of para-aortic surgical staging compared to
De Cuypere M; Lovinfosse P; Goffin F; Gennigens C; Rovira R; Duch J; Fastrez M; Gebhart G; Squifflet JL; Luyckx M; Charaf G; Crener K; Buxant F; Bucella D; Jouret M; Hustinx R; Kridelka F
Eur J Surg Oncol; 2020 May; 46(5):883-887. PubMed ID: 31784203
[TBL] [Abstract][Full Text] [Related]
18. Long-term assessment of clinical parameters and positron emission tomography parameters in predicting recurrence in uterine cervical cancer patients receiving definitive chemoradiotherapy.
Onal C; Guler OC; Torun N; Reyhan M
Nucl Med Commun; 2024 Mar; 45(3):203-210. PubMed ID: 38165168
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer.
Yilmaz B; Dağ S; Ergul N; Çermik TF
Nucl Med Commun; 2019 Mar; 40(3):219-227. PubMed ID: 30585896
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer.
Cima S; Perrone AM; Castellucci P; Macchia G; Buwenge M; Cammelli S; Cilla S; Ferioli M; Ferrandina G; Galuppi A; Salizzoni E; Rubino D; Fanti S; De Iaco P; Morganti AG
Int J Gynecol Cancer; 2018 Mar; 28(3):575-580. PubMed ID: 29372911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
